PositiveID Corporation's iglucose Mobile Health Solution for Diabetes Management to be Featured at American Association of Diabetes Educators 2011 Annual Meeting & Exhibition

Delray Beach, Florida, UNITED STATES


DELRAY BEACH, Fla., Aug. 1, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or the "Company") (Nasdaq:PSID), a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, announced today that its iglucose™ mobile health solution for diabetes management will be featured at the American Association of Diabetes Educators ("AADE") 2011 Annual Meeting & Exhibition in Las Vegas, August 3-6, 2011. iglucose, which uses the power of mobile technology to simplify diabetes management, will be showcased in the Emerging Technology Pavilion.  iglucose wirelessly communicates blood glucose readings from data-capable glucometers to the iglucose database, at which point blood glucose readings can be shared with family members and healthcare professionals, empowering individuals with diabetes to be more engaged in the self-management of their condition. The product will be demonstrated live at PositiveID's booth #4336C.

An American Association of Diabetes Educators positioning statement revealed that self-monitoring is the best way for people with diabetes, as well as healthcare professionals, to assess the ongoing efficacy of all aspects of the diabetes management regimen, including medication and patient behavior. The problem is that most people do not have the time to keep journals. iglucose solves this problem by automatically creating logs and trend reports of blood glucose readings and communicating this information, with the user's consent, to family members and healthcare professionals. Because, glucose readings can be shared more frequently, iglucose can play a role in improving care coordination and collaboration as well as aiding in remotely monitoring treatment plans. This product has not been cleared for sale by the United States Food and Drug Administration.

iglucose is currently compatible with Johnson & Johnson's One Touch® Ultra Mini®, One Touch® Ultra® 2, One Touch® Ultra®; Abbott FreeStyle Lite®, FreeStyle Freedom Lite®; Bayer's Contour®, Breeze® 2, Contour® TS; and Nipro/Home Diagnostic's TRUEresult®, TRUEtrack®, TRUEread®, TRUEbalance™. The Company is continually adding to this list of supported glucose meters.

With nearly 300 participating companies, the AADE Annual Meeting & Exhibition is an unmatched resource for gathering the latest information about innovations related to diabetes education – an exclusive, once-a-year opportunity for diabetes educators and diabetes healthcare professionals to participate in live demonstrations and face-to-face question and answer sessions with industry experts.

According to the 2011 National Diabetes Fact Sheet, 25.8 million children and adults in the United States, or 8.3% of the population, have diabetes. The total cost of diabetes in the United States in 2007 was $218 billion.

For more information on iglucose, please visit www.iglucose.com.     

About PositiveID Corporation

PositiveID Corporation develops unique medical devices and biological detection systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MicroFluidic Systems, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com. ;

The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717

Statements about PositiveID's future expectations, including the ability of iglucose to use the power of mobile technology to simplify diabetes management; the ability of iglucose to empower individuals with diabetes to be more engaged in the self-management of their condition; the likelihood that iglucose can play a role in improving care coordination and collaboration as well as aiding in remotely monitoring treatment plans; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include the Company's ability to receive FDA clearance and successfully commercialize iglucose; the ability of iglucose to function with the aforementioned glucose meters and the likelihood that the Company will add to this list of supported glucose meters; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

All trademarks are property of their respective owners.



        

Contact Data